SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC).
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS493-TPS493, 140p
- Subject
- Language
- ISSN
- 0732183X